Luminally expressed gastrointestinal biomarkers

Research output: Contribution to journalReview articlepeer-review

Standard

Luminally expressed gastrointestinal biomarkers. / Cummins, Gerard; Yung, Diana E; Cox, Ben F; Koulaouzidis, Anastasios; Desmulliez, Marc P Y; Cochran, Sandy .

In: Expert review of gastroenterology and hepatology, Vol. 11, No. 12, 14.09.2017, p. 1119-1134.

Research output: Contribution to journalReview articlepeer-review

Harvard

Cummins, G, Yung, DE, Cox, BF, Koulaouzidis, A, Desmulliez, MPY & Cochran, S 2017, 'Luminally expressed gastrointestinal biomarkers', Expert review of gastroenterology and hepatology, vol. 11, no. 12, pp. 1119-1134. https://doi.org/10.1080/17474124.2017.1373017

APA

Cummins, G., Yung, D. E., Cox, B. F., Koulaouzidis, A., Desmulliez, M. P. Y., & Cochran, S. (2017). Luminally expressed gastrointestinal biomarkers. Expert review of gastroenterology and hepatology, 11(12), 1119-1134. https://doi.org/10.1080/17474124.2017.1373017

Vancouver

Author

Cummins, Gerard ; Yung, Diana E ; Cox, Ben F ; Koulaouzidis, Anastasios ; Desmulliez, Marc P Y ; Cochran, Sandy . / Luminally expressed gastrointestinal biomarkers. In: Expert review of gastroenterology and hepatology. 2017 ; Vol. 11, No. 12. pp. 1119-1134.

Bibtex

@article{3839c483ba4c46fb9a9bd191de6bb408,
title = "Luminally expressed gastrointestinal biomarkers",
abstract = "Introduction: A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract.Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility.",
keywords = "biomarker, gastrointestinal disease, faecal calprotectin, lactoferrin, phagocyte derived protein, faecal occult blood testing, mucins, fatty acid binding proteins, microbiome, volatilome",
author = "Gerard Cummins and Yung, {Diana E} and Cox, {Ben F} and Anastasios Koulaouzidis and Desmulliez, {Marc P Y} and Sandy Cochran",
year = "2017",
month = sep,
day = "14",
doi = "10.1080/17474124.2017.1373017",
language = "English",
volume = "11",
pages = "1119--1134",
journal = "Expert review of gastroenterology and hepatology",
number = "12",

}

RIS

TY - JOUR

T1 - Luminally expressed gastrointestinal biomarkers

AU - Cummins, Gerard

AU - Yung, Diana E

AU - Cox, Ben F

AU - Koulaouzidis, Anastasios

AU - Desmulliez, Marc P Y

AU - Cochran, Sandy

PY - 2017/9/14

Y1 - 2017/9/14

N2 - Introduction: A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract.Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility.

AB - Introduction: A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract.Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility.

KW - biomarker

KW - gastrointestinal disease

KW - faecal calprotectin

KW - lactoferrin

KW - phagocyte derived protein

KW - faecal occult blood testing

KW - mucins

KW - fatty acid binding proteins

KW - microbiome

KW - volatilome

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=MEDLINE&KeyUT=MEDLINE:28849686&KeyUID=MEDLINE:28849686

U2 - 10.1080/17474124.2017.1373017

DO - 10.1080/17474124.2017.1373017

M3 - Review article

VL - 11

SP - 1119

EP - 1134

JO - Expert review of gastroenterology and hepatology

JF - Expert review of gastroenterology and hepatology

IS - 12

ER -